Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- NANOPROBES INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- JK7BK6JL14M6
- Solicitation number
- PHS2006-2
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): Cancer imaging is important for tumor detection, determination of prognosis and treatments, image guided surgery and irradiation, as well as for monitoring responses. Molecular imaging of specific targets could identify tumor types and enable selection of appropriate drugs. Although x-ray imaging is widely used and more rapid with higher resolution compared to PET, SPECT, and MRI, there are currently no targeted x-ray contrast agents. In this proposal we will develop molecular targeted agents for mammography by a nanotechnology approach using gold nanoparticles for imaging cancers. The Her 2 protein on breast cancer cells will be targeted by use of antibodies attached to biocompatible gold nanoparticles using a mouse model. This would then be useful for non-invasive in vivo detection of this mutation which occurs in about 30% of human breast cancers that could then be beneficially treated with the monoclonal antibody Herceptin(r). Molecular mammography imaging would improve on the limited sampling afforded by painful biopsies and provide more thorough detection of even small tumors and metastases missed by biopsies and other methods. It would enable earlier detection of breast cancer. Better tumor definition would also improve precise radiotherapy, surgery, and follow-up monitoring. If successful, this technology could be applied to other tumors for early detection and biochemical typing for more effective individualized treatments. To Public Health: A novel method using nanotechnology will be developed for improved non-invasive imaging and detection of breast cancer types by mammography. This should not only enable better early detection of smaller tumors and metastases without painful biopsies, but identify tumor types so that specific drugs for the type can be administered. Such a need exists to detect Her2 breast cancers, which account for about 30% of breast cancers, where the specific drug Herceptin(r) is available and improves survival.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Research funding history
47 SBIR/STTR records share this UEI (1991–2025). Reported award amounts total $12,102,185. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, National Science Foundation, Department of Energy
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards